Clinical trial results:
An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals with Angelman Syndrome (ELARA)

Summary

EudraCT number	2019-004478-24
Trial protocol	DE NL
Global end of trial date	30 June 2021

Results information

Result version number	v1 (current)
This version publication date	12 May 2022
First version publication date	12 May 2022

Trial information

Trial identification

Sponsor protocol code	OV101-18-002

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03882918
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Ovid Therapeutics Inc
Sponsor organisation address	1460 Broadway , New York, United States, 10036
Public contact	Todd F. Baumgartner, M.D., MPH, Ovid Therapeutics Inc., 1 8027525168, tbaumgartner@ovidrx.com
Scientific contact	Todd F. Baumgartner, M.D., MPH, Ovid Therapeutics Inc., 1 8027525168, tbaumgartner@ovidrx.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	13 September 2021
Is this the analysis of the primary completion data?	Yes
Primary completion date	30 June 2021
Global end of trial reached?	Yes
Global end of trial date	30 June 2021
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this study is to evaluate the long-term safety and tolerability of OV101 in individuals with AS assessed by the incidence and severity of AEs and SAEs in study participants who are at least 2 years old at the time of enrollment into this study

Protection of trial subjects:

All study subjects were required to read and sign an Informed Consent Form.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	31 January 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 4
Country: Number of subjects enrolled	Germany: 6
Country: Number of subjects enrolled	Israel: 19
Country: Number of subjects enrolled	Australia: 9
Country: Number of subjects enrolled	United States: 103
Worldwide total number of subjects	141
EEA total number of subjects	10

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	83
Adolescents (12-17 years)	17
Adults (18-64 years)	41

From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Participants in the study completed OV101-15-001 or OV101-16-001 and/or was a sibling of a participant who completed OV101-15-001, OV101-16-001, or OV101-19-001.

Pre-assignment

Screening details:

Subjects with Angelman Syndrome who completed the pharmacokinetic Study OV101-16-001 (NCT03109756) will also be permitted to participate, provided they meet all entry criteria.

Period 1

Period 1 title	Baseline & Recruitment (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Blinding implementation details:

Not blinded

Arms

Arm title	OV101

Arm description:

gaboxadol

Arm type	Experimental
Investigational medicinal product name	gaboxadol
Investigational medicinal product code	OV101
Other name	
Pharmaceutical forms	Capsule, soft
Routes of administration	Oral use

Dosage and administration details:

OV101 was supplied in 5 mg, 2 mg, and/or 0.5 mg capsules. Capsules were swallowed or the contents could be sprinkled (1 capsule to ≤1 teaspoon) on a low-fat, semi-liquid food; if enacted, this approach must have been used throughout the study.

Number of subjects in period 1	OV101
Started	141
Completed	1
Not completed	140
Consent withdrawn by subject	5
Adverse event, non-fatal	13
Other	9
Study Terminated by Sponsor	98
Protocol deviation	1
Lack of efficacy	14

Baseline characteristics

Reporting groups	
Reporting group title	OV101
Reporting group description:	
gaboxadol	

Reporting group values	OV101	Total	
Number of subjects	141	141	
Age categorical			
(NIH/OMB), there are subjects that chose multiple categories.			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	83	83	
Adolescents (12-17 years)	17	17	
Adults (18-64 years)	41	41	
From 65-84 years	0	0	
85 years and over	0	0	
Age continuous			
Units: years			
arithmetic mean	14		
standard deviation	± 9.30	-	
Gender categorical			
Sex			
Units: Subjects			
Female	57	57	
Male	84	84	

Subject analysis sets	
Subject analysis set title	Treated patients
Subject analysis set type	Per protocol
Subject analysis set description:	
gaboxadol	

Reporting group values	Treated patients		
Number of subjects	141		
Age categorical			
(NIH/OMB), there are subjects that chose multiple categories.			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		

Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	83		
Adolescents (12-17 years)	17		
Adults (18-64 years)	41		
From 65-84 years	0		
85 years and over	0		
Age continuous			
Units: years			
arithmetic mean	7.8		
standard deviation	± 3.04		
Gender categorical			
Sex			
Units: Subjects			
Female	57		
Male	84		

End points

End points reporting groups

Reporting group title	OV101
Reporting group description: gaboxadol	
Subject analysis set title	Treated patients
Subject analysis set type	Per protocol
Subject analysis set description: gaboxadol	

Primary: Incidence of adverse events in active treatment group

End point title	Incidence of adverse events in active treatment group[1]
End point description: This study was prematurely terminated.	
End point type	Primary
End point timeframe: Participants were to participate in the study for up to 166 weeks	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No Statistical Analyses was performed

End point values	OV101			
Subject group type	Reporting group			
Number of subjects analysed	141			
Units: patients				
Number of subjects analysed	141			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

All AEs that occurred from the time written informed consent and/or assent were obtained to the End Of Study visit were recorded in the source documentation and reported in the CRF.

Adverse event reporting additional description:

AEs were classified as "treatment-emergent" (i.e., TEAEs or serious TEAEs) if they occurred following the administration of IMP. All events reported in this database are treatment-emergent.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	22

Reporting groups

Reporting group title	OV101

Reporting group description:

gaboxadol

Serious adverse events	OV101		
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 141 (2.13%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Nervous system disorders			
Partial seizures			
subjects affected / exposed	2 / 141 (1.42%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Seizure cluster			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Status epilepticus			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0.05 %

Non-serious adverse events	OV101		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	106 / 141 (75.18%)		
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	11 / 141 (7.80%)		
occurrences (all)	11		
Fatigue			
subjects affected / exposed	6 / 141 (4.26%)		
occurrences (all)	6		
Gait disturbance			
subjects affected / exposed	3 / 141 (2.13%)		
occurrences (all)	3		
Crying			
subjects affected / exposed	2 / 141 (1.42%)		
occurrences (all)	2		
Discomfort			
subjects affected / exposed	2 / 141 (1.42%)		
occurrences (all)	2		
Influenza like illness			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Medical device site oedema			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Immune system disorders			
Seasonal allergy			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Social circumstances			
Patient uncooperative			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Reproductive system and breast disorders			

Penis disorder			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Respiratory, thoracic and mediastinal disorders			
Nasal congestion			
subjects affected / exposed	2 / 141 (1.42%)		
occurrences (all)	2		
Rhinorrhoea			
subjects affected / exposed	2 / 141 (1.42%)		
occurrences (all)	2		
Atelectasis			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Cough			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Hypoxia			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Sleep apnoea syndrome			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Psychiatric disorders			
Agitation			
subjects affected / exposed	8 / 141 (5.67%)		
occurrences (all)	8		
Irritability			
subjects affected / exposed	8 / 141 (5.67%)		
occurrences (all)	8		
Middle insomnia			
subjects affected / exposed	7 / 141 (4.96%)		
occurrences (all)	7		
Sleep disorder			
subjects affected / exposed	7 / 141 (4.96%)		
occurrences (all)	7		
Aggression			

subjects affected / exposed	6 / 141 (4.26%)			
occurrences (all)	6			
Insomnia				
subjects affected / exposed	6 / 141 (4.26%)			
occurrences (all)	6			
Anxiety				
subjects affected / exposed	5 / 141 (3.55%)			
occurrences (all)	5			
Abnormal behaviour				
subjects affected / exposed	4 / 141 (2.84%)			
occurrences (all)	4			
Inappropriate affect				
subjects affected / exposed	3 / 141 (2.13%)			
occurrences (all)	3			
Dermatillomania				
subjects affected / exposed	2 / 141 (1.42%)			
occurrences (all)	2			
Enuresis				
subjects affected / exposed	2 / 141 (1.42%)			
occurrences (all)	2			
Initial insomnia				
subjects affected / exposed	2 / 141 (1.42%)			
occurrences (all)	2			
Decreased interest				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Disruptive mood dysregulation disorder				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Intentional self-injury				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Nail picking				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			

Stubbornness			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Terminal insomnia			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Tic			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Investigations			
Weight decreased			
subjects affected / exposed	3 / 141 (2.13%)		
occurrences (all)	3		
Activated partial thromboplastin time prolonged			
subjects affected / exposed	2 / 141 (1.42%)		
occurrences (all)	2		
Alanine aminotransferase increased			
subjects affected / exposed	2 / 141 (1.42%)		
occurrences (all)	2		
Blood glucose decreased			
subjects affected / exposed	2 / 141 (1.42%)		
occurrences (all)	2		
Blood thyroid stimulating hormone increased			
subjects affected / exposed	2 / 141 (1.42%)		
occurrences (all)	2		
Gamma-glutamyltransferase increased			
subjects affected / exposed	2 / 141 (1.42%)		
occurrences (all)	2		
Amylase increased			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		

Blood creatine increased			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Blood insulin increased			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Blood potassium increased			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Blood uric acid increased			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Mean cell volume increased			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Menstruation normal			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Neutrophil count decreased			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Weight increased			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
White blood cell count increased			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	5 / 141 (3.55%)		
occurrences (all)	5		
Contusion			
subjects affected / exposed	2 / 141 (1.42%)		
occurrences (all)	2		
laceration			

subjects affected / exposed	2 / 141 (1.42%)		
occurrences (all)	2		
Animal bite			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Ankle fracture			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Bite			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Concussion			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Foot fracture			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Head injury			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Joint injury			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Ligament rupture			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Skin abrasion			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Tooth fracture			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Congenital, familial and genetic disorders			
Developmental hip dysplasia			

subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Cardiac disorders			
Cardiac arrest			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Tachycardia			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Nervous system disorders			
Seizure			
subjects affected / exposed	10 / 141 (7.09%)		
occurrences (all)	10		
Somnolence			
subjects affected / exposed	8 / 141 (5.67%)		
occurrences (all)	8		
Generalised tonic-clonic seizure			
subjects affected / exposed	6 / 141 (4.26%)		
occurrences (all)	6		
Petit mal epilepsy			
subjects affected / exposed	6 / 141 (4.26%)		
occurrences (all)	6		
Tremor			
subjects affected / exposed	6 / 141 (4.26%)		
occurrences (all)	6		
Headache			
subjects affected / exposed	3 / 141 (2.13%)		
occurrences (all)	3		
Lethargy			
subjects affected / exposed	3 / 141 (2.13%)		
occurrences (all)	3		
Myoclonus			
subjects affected / exposed	3 / 141 (2.13%)		
occurrences (all)	3		
Partial seizures			

subjects affected / exposed	3 / 141 (2.13%)			
occurrences (all)	3			
Clonic convulsion				
subjects affected / exposed	2 / 141 (1.42%)			
occurrences (all)	2			
Dyskinesia				
subjects affected / exposed	2 / 141 (1.42%)			
occurrences (all)	2			
Seizure cluster				
subjects affected / exposed	2 / 141 (1.42%)			
occurrences (all)	2			
Status epilepticus				
subjects affected / exposed	2 / 141 (1.42%)			
occurrences (all)	2			
Action tremor				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Altered state of consciousness				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Atonic seizures				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Cognitive disorder				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Hypertonia				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Intention tremor				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Syncope				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Tardive dyskinesia				

subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Tonic convulsion			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 141 (1.42%)		
occurrences (all)	2		
Increased tendency to bruise			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Eye disorders			
Conjunctival haemorrhage			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Photophobia			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Gastrointestinal disorders			
Vomiting			
subjects affected / exposed	13 / 141 (9.22%)		
occurrences (all)	13		
Constipation			
subjects affected / exposed	9 / 141 (6.38%)		
occurrences (all)	9		
Diarrhoea			
subjects affected / exposed	4 / 141 (2.84%)		
occurrences (all)	4		
Gastrooesophageal reflux disease			
subjects affected / exposed	3 / 141 (2.13%)		
occurrences (all)	3		
Nausea			

subjects affected / exposed	3 / 141 (2.13%)			
occurrences (all)	3			
Dental caries				
subjects affected / exposed	2 / 141 (1.42%)			
occurrences (all)	2			
Retching				
subjects affected / exposed	2 / 141 (1.42%)			
occurrences (all)	2			
Toothache				
subjects affected / exposed	2 / 141 (1.42%)			
occurrences (all)	2			
Abdominal discomfort				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Anal incontinence				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Aphthous ulcer				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Eructation				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Gastric ulcer				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Gastritis				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Glossitis				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Haematemesis				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Hiatus hernia				

subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Ileus			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Incarcerated hiatus hernia			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Mallory-Weiss syndrome			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Tongue ulceration			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Tooth development disorder			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Tooth impacted			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	5 / 141 (3.55%)		
occurrences (all)	5		
Dermatitis allergic			
subjects affected / exposed	2 / 141 (1.42%)		
occurrences (all)	2		
Dermatitis diaper			
subjects affected / exposed	2 / 141 (1.42%)		
occurrences (all)	2		
Alopecia			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Decubitus ulcer			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		

Eczema			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	2 / 141 (1.42%)		
occurrences (all)	2		
Urinary retention			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Musculoskeletal and connective tissue disorders			
Arthritis			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Joint swelling			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Muscular weakness			
subjects affected / exposed	1 / 141 (0.71%)		
occurrences (all)	1		
Infections and infestations			
Upper respiratory tract infection			
subjects affected / exposed	14 / 141 (9.93%)		
occurrences (all)	14		
Nasopharyngitis			
subjects affected / exposed	11 / 141 (7.80%)		
occurrences (all)	11		
corona virus infection			
subjects affected / exposed	9 / 141 (6.38%)		
occurrences (all)	9		
Urinary tract infection			
subjects affected / exposed	6 / 141 (4.26%)		
occurrences (all)	6		
Gastroenteritis			
subjects affected / exposed	5 / 141 (3.55%)		
occurrences (all)	5		

Pneumonia				
subjects affected / exposed	4 / 141 (2.84%)			
occurrences (all)	4			
Otitis media				
subjects affected / exposed	4 / 141 (2.84%)			
occurrences (all)	4			
Conjunctivitis				
subjects affected / exposed	2 / 141 (1.42%)			
occurrences (all)	2			
Enterobiasis				
subjects affected / exposed	2 / 141 (1.42%)			
occurrences (all)	2			
Fungal infection				
subjects affected / exposed	2 / 141 (1.42%)			
occurrences (all)	2			
Gastroenteritis viral				
subjects affected / exposed	2 / 141 (1.42%)			
occurrences (all)	2			
Influenza				
subjects affected / exposed	2 / 141 (1.42%)			
occurrences (all)	2			
lung infection				
subjects affected / exposed	2 / 141 (1.42%)			
occurrences (all)	2			
Pharyngitis streptococcal				
subjects affected / exposed	2 / 141 (1.42%)			
occurrences (all)	2			
Sinusitis				
subjects affected / exposed	2 / 141 (1.42%)			
occurrences (all)	2			
Viral infection				
subjects affected / exposed	2 / 141 (1.42%)			
occurrences (all)	2			
Tooth infection				
subjects affected / exposed	2 / 141 (1.42%)			
occurrences (all)	2			

Adenovirus infection				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Bronchitis				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Campylobacter gastroenteritis				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Cellulitis				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Device related infection				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Ear infection				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Gingivitis				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Helicobacter infection				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Laryngitis viral				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Leishmaniasis				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Oral herpes				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			
Oral infection				
subjects affected / exposed	1 / 141 (0.71%)			
occurrences (all)	1			

Pharyngitis subjects affected / exposed occurrences (all)	1 / 141 (0.71%) 1		
Respiratory tract infection viral subjects affected / exposed occurrences (all)	1 / 141 (0.71%) 1		
Rhinovirus infection subjects affected / exposed occurrences (all)	1 / 141 (0.71%) 1		
Urinary tract infection fungal subjects affected / exposed occurrences (all)	1 / 141 (0.71%) 1		
Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all)	6 / 141 (4.26%) 6		
Abnormal loss of weight subjects affected / exposed occurrences (all)	5 / 141 (3.55%) 5		
Dehydration subjects affected / exposed occurrences (all)	3 / 141 (2.13%) 3		
Hypercalcaemia subjects affected / exposed occurrences (all)	1 / 141 (0.71%) 1		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

http://www.ncbi.nlm.nih.gov/pubmed/33395098